Trial 5U-11-1

A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi-Center Study to Evaluate the Efficacy of Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Agustin Garcia, M.D.
Other Trial Staff: Kristy Watkins, R.N., Grace Facio, R.N., Marissa Aldana, D.M., Yvonne Flores, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.